The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Eloxx Pharmaceuticals Announces Pipeline and Financing Updates
Jul 11, 2024•almost 2 years ago
Contract Type
partnership
MassachusettsBiotechnologyHealth CareTherapeutics
Description
Eloxx Pharmaceuticals has dosed the first healthy volunteers in the Phase 1 trial for ZKN-013 and received positive written FDA feedback. They have also secured a binding commitment for additional $3.2 million financing to advance their clinical programs.
Company Information
Company
Eloxx Pharmaceuticals
Location
Massachusetts, United States
About
Eloxx Pharmaceuticals, Inc. is a leader in ribosomal RNA-targeted genetic therapies for rare diseases with nonsense mutations.
Predictive Intelligence
Strategic
ML-powered predictions for Eloxx Pharmaceuticals's next move
MassachusettsBiotechnologyHealth CareTherapeutics